Disclose additional clinical results from the Phase 1 RTX-240 trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 23 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company expects to disclose additional clinical results in early 2021 and plans to present the data at a medical conference”
What we found
Evidence strength A What the grades mean
The company announced initial RTX-240 clinical data in March 2021, before the June 2021 deadline, and presented it at AACR in April 2021.
-
A Rubius Therapeutics, Inc. 10-Q filed 2021-08-09
“We presented initial safety and efficacy data from the ongoing RTX-240 Phase 1/2 clinical trial in relapsed/refractory or locally advanced solid tumors at the American Association for Cancer Research, or AACR, conference in April 2021.” ✓ confirmed on the page
-
A Rubius Therapeutics, Inc. 10-Q filed 2021-11-08
“In March 2021, we announced initial clinical data from the RTX-240 clinical trial that we believe provides initial proof-of-concept” ✓ confirmed on the page
-
A Rubius Therapeutics, Inc. 10-Q filed 2021-11-08
“The data reported in March 2021 included initial safety (n=16) and efficacy (n=15) data from the RTX-240 Phase 1/2 clinical trial” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Disclose
- Deliverable
- Additional clinical results from Phase 1 RTX-240 solid tumor trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: as more patients are enrolled and data mature
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Rubius Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C709401-024222 · Corrections policy